Government of Saskatchewan ministries, Crown corporations and organizations are working to minimize the impacts of the postal service disruption.
Les ministères, les sociétés d’État et les organismes du gouvernement de la Saskatchewan travaillent à réduire au minimum les répercussions de l’interruption des services postaux.
Google Translate Disclaimer
A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:
Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.
Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).
Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.
Released on February 21, 2012
The Saskatchewan Drug Plan is making changes to the Saskatchewan Drug Formulary related to oxycodone, a prescription medication used in the treatment of moderate to severe pain. While this medication plays an important role in the management of pain, it can also be the target of misuse and abuse.
This change coincides with the drug manufacturer's plan to discontinue OxyContin at the end of February 2012 and replace it with a new formulation. The replacement, OxyNEO, is designed by the manufacturer to be a difficult-to-crush tablet which will make it harder to abuse. Both drugs are potentially addictive narcotic painkillers.
Saskatchewan's approach to limit access to oxycodone is in line with that of other provinces and territories.
Starting February 29, 2012, the Saskatchewan Drug Plan will list OxyNEO under the Exception Drug Status program. Cancer or palliative pain patients will receive coverage for OxyNEO under this program. New patients who do not meet these criteria would be responsible for the full cost of an OxyNEO prescription.
Existing patients who have received coverage of OxyContin in the three months prior to March 1, 2012, will be eligible for coverage of OxyNEO.
OxyNEO is not interchangeable with OxyContin. Saskatchewan Drug Plan beneficiaries changing to OxyNEO will require a new prescription if their physician considers it appropriate.
OxyNEO is being priced the same as OxyContin. Monthly cost of this drug ranges between $80 and $195.
Patients with questions about their coverage should contact the Drug Plan and Extended Benefits Branch at 1-800-667-7581.
-30-
For more information, contact:
Tyler McMurchy
Health
Regina
Phone: 306-787-4083
Email: tyler.mcmurchy@gov.sk.ca
We need your feedback to improve saskatchewan.ca. Help us improve
